RxDoctor Payments Data

Nathan Greczek, DO

Family Medicine · Peckville, PANPI 1255654539

Payments from drug & device makers

$22,964in general payments, 2019–2025

Across 1,541 payments — averaging $14.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$2K
  • AstraZeneca$2K
  • Pfizer$1K
  • GSK$1K
  • Amgen$1K
  • plus $11K from 53 others

What the payments were for

  • Food & beverage$22,958100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk242$3,371
AbbVie(2 entities)140$2,176
AstraZeneca85$1,934
Pfizer127$1,393
GSK93$1,390
Amgen89$1,363
Boehringer Ingelheim83$1,126
Lilly USA, LLC72$1,013
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC86$1,007
Bayer40$711
Astellas Pharma US Inc34$577
Amarin Pharma, Inc.33$415
Novartis24$395
Lundbeck LLC20$342
Johnson & Johnson23$324
Eisai Inc.17$317
Exact Sciences19$313
Sunovion Pharmaceuticals Inc.22$292
Kowa Pharmaceuticals America, Inc.20$289
Nestle Healthcare Nutrition Inc.20$287
Aimmune Therapeutics, Inc.16$278
Abbott15$259
Axsome Therapeutics, Inc.15$256
Otsuka America Pharmaceutical, Inc.12$249
Merck20$209
Sumitomo Pharma America, Inc.12$190
Teva Pharmaceuticals USA, Inc.12$185
Supernus Pharmaceuticals, Inc.12$179
Radius Health, Inc.10$176
Sanofi-aventis U.S. LLC10$172
Biohaven Pharmaceuticals, Inc.16$168
Ironwood Pharmaceuticals, Inc10$167
Biohaven Pharmaceutical Holding Company Ltd.13$166
Dexcom, Inc.8$149
Takeda Pharmaceuticals U.S.A., Inc.9$130
Phathom Pharmaceuticals, Inc.8$111
IBSA Pharma Inc.7$106
Verona Pharma, Inc.3$78
Avanir Pharmaceuticals, Inc.6$73
Esperion Therapeutics, Inc.5$73
Actelion Pharmaceuticals US, Inc.3$72
E.r. Squibb & Sons, L.L.C.5$72
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$47
Regeneron Healthcare Solutions, Inc.3$41
Globus Medical2$36
Insmed, Inc.2$36
Idorsia Pharmaceuticals US Inc2$34
Sanofi Pasteur Inc.2$29
Abiomed1$23
Biogen1$23
Shield Therapeutics Inc1$20
Almatica Pharma LLC1$19
Xeris Pharmaceuticals, Inc.1$17
Insulet Corporation1$16
Shire North American Group Inc1$15
Paratek Pharmaceuticals, Inc.1$14
Neurocrine Biosciences, Inc.1$14
Mylan Specialty L.p.1$13
Genentech USA, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,964 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$84,315
Medicare patients
211
Services billed
1,097

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban188$140,643
OzempicSemaglutide82$107,508
Trelegy ElliptaFluticasone/Umeclidin/Vilanter160$105,010
XifaxanRifaximin21$104,093
MounjaroTirzepatide46$67,214
JardianceEmpagliflozin78$60,304
XareltoRivaroxaban61$58,642
RybelsusSemaglutide23$45,260
TrulicityDulaglutide33$40,506
LinzessLinaclotide39$28,916
FarxigaDapagliflozin Propanediol21$24,602
JanuviaSitagliptin Phosphate15$24,249
MyrbetriqMirabegron41$21,735
Combivent RespimatIpratropium/Albuterol Sulfate24$14,835
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$14,724

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$3,371$152,768105 claims
PfizerEliquis$1,393$140,643188 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,390$128,678200 claims
Lilly USA, LLCMounjaro, Trulicity$1,013$107,72079 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,007$104,09321 claims
Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta$1,126$83,436118 claims
Johnson & JohnsonXarelto$324$58,64261 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,934$35,35036 claims
AbbVieLinzess$2,176$28,91639 claims
MerckJanuvia$209$24,24915 claims
Astellas Pharma US IncMyrbetriq$577$21,73541 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$130$6,80014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Peckville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →